Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
But politics could derail the one thing to unlock it.
Enhanced cryo–electron microscopy promises to bring previously elusive proteins into view.